Alpha-1 Antitrypsin Deficiency
Conditions
Keywords
Alpha-1 antitrypsin deficiency, Adeno-associated virus vector, AAV, Gene therapy, Human gene transfer
Brief summary
Assessment of the safety and efficacy of intramuscular (IM) administration of a recombinant adenoassociated virus (rAAV) alpha-1 antitrypsin (AAT) vector (rAAV1-CB-hAAT) in AAT-deficient adults at three dosage levels \[6.0 × 10e11, 1.9 × 10e12 and 6.0 × 10e12 vector genome particles (vg) per kg body weight\]. Funding Sources - The FDA Office of Orphan Products Development and NIH National Heart, Lung, and Blood Institute
Detailed description
The study is a non-randomized, open-label, multi-center, sequential, three-arm, Phase 2 clinical trial evaluating the safety and efficacy of administration of a rAAV1-CB-hAAT vector administered by IM injection. Each participant will receive rAAV1-CB-hAAT on a single occasion. Three groups of three subjects each will receive rAAV1-CB-hAAT at dosage levels of 6 x 10e11 vg/kg, 1.9 x 10e12 vg/kg or 6 x 10e12 vg/kg by IM injection. Subjects in group 1 will receive a total of 10 IM injections distributed across a single muscle site, subjects in group 2 will receive a total of 32 IM injections distributed across three muscle sites, and subjects in group 3 will receive 100 IM injections distributed across 10 muscle sites. Each injection will be given in a volume of 1.35 mL, at the appropriate vector concentration to achieve the desired total vector dose. The three groups were enrolled sequentially, with review of safety data by a Data and Safety Monitoring Board before enrollment of each higher dosage level group. Safety was monitored by evaluation of adverse events, hematology and clinical chemistry parameters, histological examination of muscle biopsies, and measurement of serum antibodies to AAT. Efficacy was measured by evaluation of serum concentrations of M-specific AAT and total AAT, and serum AAT phenotype determined on isoelectric focusing gels. Additional information collected included presence of the vector in blood or semen, changes in serum anti-AAV antibody titers, and changes in T cell responses to AAV and AAT.
Interventions
DRUGrAAV1-CB-hAAT
Recombinant adeno-associated virus vector expressing human alpha-1 antitrypsin
Sponsors
National Heart, Lung, and Blood Institute (NHLBI)
Beacon Therapeutics
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Have a diagnosis of AAT-deficiency, as defined by a serum AAT level of less than 11 µM and a phenotype or genotype either homozygous for PI\*Z or compound heterozygous consisting of PI\*Z and another allele known to be associated with disease 2. Be at least 18 and not more than 75 years of age 3. Have a forced expiratory volume at one second (FEV1) \>25% of predicted value (post bronchodilator) 4. Weigh ≤ 90 kg 5. Not receiving AAT augmentation therapy currently or with the past 3 months, and not planning to begin such therapy for at least 12 months after administration of rAAV1-CB-hAAT 6. Be willing to discontinue aspirin, aspirin-containing products, and other drugs that may alter platelet function, 7 days prior to dosing, resuming no earlier than 24 hours after the dose has been administered 7. Have acceptable laboratory parameters: * Hemoglobin ≥ 11.2 g/dL for females, ≥ 12.8 g/dL for males, * White blood cell count 3,300 - 12,000 cells/mm3, * Platelet count 125,000 - 550,000/mm3, * Serum creatine kinase (CK) ≤ 3 times upper normal range for study laboratory, * Alanine aminotransferase (ALT) ≤ 2 times upper normal range for study laboratory, * Serum bilirubin ≤ 1.5 times upper normal range for study laboratory, * Serum creatinine within normal range for study laboratory, * Prothrombin time (PT) ≤ 14.5 seconds and partial thromboplastin time (PTT) ≤ 36 seconds, * Normal urine dipstick (negative glucose, negative hemoglobin, and negative or trace protein), 8. For females of childbearing potential: * A negative pregnancy test (urine or serum) at screening and at baseline (within 2 days before administration of study agent) * Agreement to consistently use barrier contraception (condoms, diaphragm or cervical cap with spermicide) or another form of contraception (e.g. intrauterine device or hormonal contraception) from the screening visit until 12 months after administration of rAAV1-CB-hAAT, for sexual activity that could lead to pregnancy 9. For males of reproductive potential, agreement to consistently use barrier contraception (condoms with spermicide) for 12 months after administration of rAAV1-CB-hAAT, for sexual activity that could lead to pregnancy, 10. Provide signed informed consent before screening
Exclusion criteria
1. Prior receipt of any AAV gene therapy product 2. Use of anticoagulants or anti-platelet agents within 7 days prior to study agent administration 3. History of immune response to human AAT augmentation therapy as indicated by clinical history of an adverse immune response to infusion and/or decreased therapeutic effect in combination with documentation of serum anti-AAT antibodies 4. Use of acute oral or intravenous antibiotic therapy for a respiratory infection within 28 days prior to study agent administration (long-term maintenance or chronic suppressive oral antibiotics, and antibiotics for a non-respiratory indication, are allowed) 5. Use of oral or systemic corticosteroids within 28 days prior to study agent administration 6. Use of any investigational agent, or any immunosuppressive drug(s), within 3 months prior to enrollment 7. For females of childbearing potential, a positive pregnancy test at screening or baseline (within 2 days before rAAV1-CB-hAAT administration) Note: At the Cincinnati Children's Hospital Medical Center site, women of childbearing potential were not permitted to enroll in the study. 8. Females who are breast feeding 9. Have a significant abnormal EKG finding at screening and/or cardiac disease (e.g. recent myocardial infarction or CHF) within past 6 months 10. Have had pulmonary edema or a pulmonary embolism within the past 6 months 11. Have a history of immunodeficiency or other medical condition which leads the investigator to believe that the participant cannot comply with the protocol requirements or that may place the participant at an unacceptable risk for participation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Frequency of Grade 3 or 4 Adverse Events | During 1 year after study agent administration |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in Serum M-specific Alpha-1 Antitrypsin Concentration | During months 6-12 after study agent adminsitration | Results are the mean ± SD for pre-treatment (Screening and Baseline) and Months 6-12 values and mean ± SE for the difference between the pre-treatment and months 6-12 means for 2 subjects in the low dose group and 3 subjects in each of the other two groups. The monoclonal antibody used to determine serum M-specific AAT concentrations has very little cross-reactivity with Z type AAT but cross-reacts strongly with S type AAT, causing results for this assay to be spuriously high for subject 303 in the low dose group. |
| Changes in Serum Total Alpha-1 Antitrypsin Concentrations | During months 6-12 after study agent adminstration | Results are the mean ± SD for pre-treatment (Screening and Baseline) and Months 6-12 data and mean ± SE for the difference between the pre-treatment and months 6-12 means for 3 subjects per group. |
Countries
Ireland, United States
Participant flow
Recruitment details
Subjects were recruited from two clinical trial sites (University of Massachusetts Medical Center and Cincinnati Children's Hospital Medical Center).
Participants by arm
| Arm | Count |
|---|---|
| Low Dose rAAV1-CB-hAAT at dosage level of 6 x 10e11 vg/kg administered as 10 IM injections distributed across a single muscle site | 3 |
| Middle Dose rAAV1-CB-hAAT at dosage level of 1.9 x 10e12 vg/kg administered as 32 IM injections distributed across three muscle sites | 3 |
| High Dose rAAV1-CB-hAAT at dosage level of 6 x 10e12 vg/kg administered as 100 IM injections distributed across 10 muscle sites | 3 |
| Total | 9 |
Baseline characteristics
| Characteristic | Low Dose | Middle Dose | High Dose | Total |
|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 1 Participants | 0 Participants | 0 Participants | 1 Participants |
| Age, Categorical Between 18 and 65 years | 2 Participants | 3 Participants | 3 Participants | 8 Participants |
| Age, Continuous | 50.3 years STANDARD_DEVIATION 26.4 | 48.7 years STANDARD_DEVIATION 9.3 | 54.3 years STANDARD_DEVIATION 3.5 | 51.1 years STANDARD_DEVIATION 14.3 |
| Alpha-1 antitrypsin phenotype SZ | 1 participants | 0 participants | 0 participants | 1 participants |
| Alpha-1 antitrypsin phenotype ZZ | 2 participants | 3 participants | 3 participants | 8 participants |
| Serum total alpha-1 antitrypsin concentration | 6.56 microMolar STANDARD_DEVIATION 2 | 3.54 microMolar STANDARD_DEVIATION 0.12 | 3.45 microMolar STANDARD_DEVIATION 0.25 | 4.31 microMolar STANDARD_DEVIATION 1.88 |
| Sex: Female, Male Female | 3 Participants | 2 Participants | 2 Participants | 7 Participants |
| Sex: Female, Male Male | 0 Participants | 1 Participants | 1 Participants | 2 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 3 / 3 | 3 / 3 | 3 / 3 |
| serious Total, serious adverse events | 0 / 3 | 0 / 3 | 1 / 3 |
Outcome results
Primary
Frequency of Grade 3 or 4 Adverse Events
Time frame: During 1 year after study agent administration
Population: Analysis based on all subjects enrolled in study.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Low Dose | Frequency of Grade 3 or 4 Adverse Events | 0 participants |
| Middle Dose | Frequency of Grade 3 or 4 Adverse Events | 0 participants |
| High Dose | Frequency of Grade 3 or 4 Adverse Events | 1 participants |
Secondary
Changes in Serum M-specific Alpha-1 Antitrypsin Concentration
Results are the mean ± SD for pre-treatment (Screening and Baseline) and Months 6-12 values and mean ± SE for the difference between the pre-treatment and months 6-12 means for 2 subjects in the low dose group and 3 subjects in each of the other two groups. The monoclonal antibody used to determine serum M-specific AAT concentrations has very little cross-reactivity with Z type AAT but cross-reacts strongly with S type AAT, causing results for this assay to be spuriously high for subject 303 in the low dose group.
Time frame: During months 6-12 after study agent adminsitration
Population: One subject in low dose group had AAT phenotype SZ, which made measurement of M-specific serum alpha-1 antitrypsin concentration invalid.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Low Dose | Changes in Serum M-specific Alpha-1 Antitrypsin Concentration | 31.5 nanomolar | Standard Error 7.56 |
| Middle Dose | Changes in Serum M-specific Alpha-1 Antitrypsin Concentration | 71.8 nanomolar | Standard Error 22.73 |
| High Dose | Changes in Serum M-specific Alpha-1 Antitrypsin Concentration | 239.2 nanomolar | Standard Error 27.57 |
Secondary
Changes in Serum Total Alpha-1 Antitrypsin Concentrations
Results are the mean ± SD for pre-treatment (Screening and Baseline) and Months 6-12 data and mean ± SE for the difference between the pre-treatment and months 6-12 means for 3 subjects per group.
Time frame: During months 6-12 after study agent adminstration
Population: Analysis based on all subjects enrolled in study.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Low Dose | Changes in Serum Total Alpha-1 Antitrypsin Concentrations | 0.33 micromolar | Standard Error 1.14 |
| Middle Dose | Changes in Serum Total Alpha-1 Antitrypsin Concentrations | 0.16 micromolar | Standard Error 0.1 |
| High Dose | Changes in Serum Total Alpha-1 Antitrypsin Concentrations | 0.19 micromolar | Standard Error 0.16 |